Skip to content
OpenCapital
Get started

Kyverna Therapeutics, Inc. KYTX Cash ratio

Cash ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Gilead Sciences logo
Gilead SciencesGILD
0.8×+0.2×
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
2.1×-2.1×
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
2×-0.6×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
1.5×+0.1×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
3.4×0.0×

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0×0.0×
Current ratio8.1×+0.7×

Where this comes from

Calculated from Kyverna Therapeutics, Inc.’s reported figures.

cash and equivalents/total current liabilities=1.1×

Based on the most recent quarter.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s cash ratio?
Kyverna Therapeutics, Inc. (KYTX) reported cash ratio of 1.1× in Q1 2026.
How has Kyverna Therapeutics, Inc.'s cash ratio changed year-over-year?
Kyverna Therapeutics, Inc.'s cash ratio decreased by 36.5% year-over-year, from 1.7× to 1.1×.
What is the long-term trend for Kyverna Therapeutics, Inc.'s cash ratio?
Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s cash ratio has grown at a 39.6% compound annual growth rate (CAGR), from 1.7× to 3.4×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.